Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4018MR)

This product GTTS-WQ4018MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4018MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11493MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ12277MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ1563MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13734MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ6053MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ8888MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ13658MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ14583MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW